Related references
Note: Only part of the references are listed.CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure
Sandor Batkai et al.
EUROPEAN HEART JOURNAL (2021)
CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure
Sandor Batkai et al.
EUROPEAN HEART JOURNAL (2021)
Preclinical development of a miR-132 inhibitor for heart failure treatment
Ariana Foinquinos et al.
NATURE COMMUNICATIONS (2020)
Engineered Circular RNA Sponges Act as miRNA Inhibitors to Attenuate Pressure Overload-Induced Cardiac Hypertrophy
Annadoray Lavenniah et al.
MOLECULAR THERAPY (2020)
Heart failure drug treatment
Patrick Rossignol et al.
LANCET (2019)
RNA-based diagnostic and therapeutic strategies for cardiovascular disease
Dongchao Lu et al.
NATURE REVIEWS CARDIOLOGY (2019)
Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure
Serge Masson et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression
Geula Hanin et al.
GUT (2018)
microRNA-132: a key noncoding RNA operating in the cellular phase of Alzheimer's disease
Evgenia Salta et al.
FASEB JOURNAL (2017)
FDA-Approved Oligonucleotide Therapies in 2017
Cy A. Stein et al.
MOLECULAR THERAPY (2017)
Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia
Sabine Sewing et al.
PLOS ONE (2017)
Safety of antisense oligonucleotide and siRNA-based therapeutics
Xuan Chi et al.
DRUG DISCOVERY TODAY (2017)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC
Piotr Ponikowski et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
Silencing of microRNA-132 reduces renal fibrosis by selectively inhibiting myofibroblast proliferation
Roel Bijkerk et al.
KIDNEY INTERNATIONAL (2016)
The war against heart failure: the Lancet lecture
Eugene Braunwald
LANCET (2015)
Antisense Oligonucleotide Therapies: The Promise and the Challenges from a Toxicologic Pathologist's Perspective
Kendall S. Frazier
TOXICOLOGIC PATHOLOGY (2015)
Angiotensin II Regulates microRNA-132/-212 in Hypertensive Rats and Humans
Tilde V. Eskildsen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Treatment of HCV Infection by Targeting MicroRNA
Harry L. A. Janssen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy
Ahmet Ucar et al.
NATURE COMMUNICATIONS (2012)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Systolic Heart Failure
John J. V. McMurray
NEW ENGLAND JOURNAL OF MEDICINE (2010)
MicroRNAs in the human heart - A clue to fetal gene reprogramming in heart failure
Thomas Thum et al.
CIRCULATION (2007)
Share Paper
